| Symbol | AARD |
|---|---|
| Name | AARDVARK THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 4370 LA JOLLA VILLAGE DRIVE,SUITE 1050, SAN DIEGO, California, 92122, United States |
| Telephone | (858) 225-7696 |
| Fax | — |
| — | |
| Website | https://www.aardvarktherapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001774857 |
| Description | Aardvark Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We have focused our efforts on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Our wholly-owned lead product candidate, ARD-101 (denatonium acetate monohydrate), is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which we have initiated a Phase 3 clinical trial for hyperphagia associated with Prader-Willi Syndrome (PWS). We also intend to evaluate ARD-101 in a Phase 2 clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation (HO). Additional info from NASDAQ: |
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
Read moreLAWSUIT ALERT: Investors who lost over $100,000 with Aardvark Therapeutics, Inc. (NASDAQ: AARD) between February 2025 and May 2026, should contact the Shareholders Foundation
Read moreAARD Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Aardvark Therapeutics Securities Lawsuit - Contact SueWallSt
Read moreBronstein, Gewirtz & Grossman LLC Urges Aardvark Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Read moreLevi & Korsinsky Reminds Aardvark Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 13, 2026 - AARD
Read morePomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors - AARD
Read moreAARD Investor Notice: Hagens Berman Alerts Investors in Aardvark Therapeutics (NASDAQ: AARD) to Filing of Securities Class Action
Read moreAardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Read moreSecurities Fraud Investigation Into Aardvark Therapeutics, Inc. (AARD) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Read moreSecurities Fraud Investigation Into Aardvark Therapeutics, Inc. (AARD) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06828861 | ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Tri… | Phase3 | Hyperphagia | Terminated | 2024-12-20 | 2026-05-07 | ClinicalTrials.gov |
| NCT06126653 | A Study to Evaluate ARD-501 in Patients With Autism Spectrum Disorder | Phase2 | Autism Spectrum Disorder | Completed | 2024-08-01 | 2025-01-13 | ClinicalTrials.gov |
| NCT07197034 | The Hunger Elimination or Reduction Objective (HERO ) Open -Label Extension (OL… | Phase3 | Hyperphagia | Terminated | 2024-07-23 | 2026-04-15 | ClinicalTrials.gov |
| NCT05153434 | A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome | Phase2 | Prader-Willi Syndrome | Completed | 2022-05-27 | 2024-09-24 | ClinicalTrials.gov |
| NCT05215847 | Study to Evaluate ARD-101 in Adults Receiving Bariatric Surgery | Phase2 | Bariatric Surgery | Completed | 2022-03-01 | 2023-02-03 | ClinicalTrials.gov |
| NCT05121441 | Study to Evaluate ARD-101 in Adults With Obesity | Phase2 | Obesity | Completed | 2021-11-15 | 2022-11-09 | ClinicalTrials.gov |
| NCT01129765 | Home Usability of a Nasal Lavage System in Children | — | Nasal Congestion | Completed | 2009-07-01 | 2009-08-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| ARD-101 | Other | Phase PHASE3 | Hyperphagia | TERMINATED | NCT06828861 |
| Placebo | Other | Phase PHASE3 | Hyperphagia | TERMINATED | NCT06828861 |
| ARD-101 | Other | Phase PHASE3 | Hyperphagia | TERMINATED | NCT07197034 |
| Use of an automatic nasal irrigator/aspirator | Other | Preclinical | Nasal Congestion | COMPLETED | NCT01129765 |
| Placebo | Other | Phase PHASE2 | Obesity | COMPLETED | NCT05121441 |
| ARD-101 | Other | Phase PHASE2 | Obesity | COMPLETED | NCT05121441 |
| ARD-101 | Other | Phase PHASE2 | Bariatric Surgery | COMPLETED | NCT05215847 |
| Placebo | Other | Phase PHASE2 | Autism Spectrum Disorder | COMPLETED | NCT06126653 |
| High Dose ARD-501 | Other | Phase PHASE2 | Autism Spectrum Disorder | COMPLETED | NCT06126653 |
| Low Dose ARD-501 | Other | Phase PHASE2 | Autism Spectrum Disorder | COMPLETED | NCT06126653 |
| ARD-101 | Other | Phase PHASE2 | Prader-Willi Syndrome | COMPLETED | NCT05153434 |
| ARD-101 | Other | Phase PHASE3 | Hyperphagia | SUSPENDED | NCT07197034 |
| ARD-101 | Other | Phase PHASE3 | Hyperphagia | SUSPENDED | NCT06828861 |
| Placebo | Other | Phase PHASE3 | Hyperphagia | SUSPENDED | NCT06828861 |
| High Dose ARD-501 | DRUG | Phase PHASE2 | Autism Spectrum Disorder | COMPLETED | NCT06126653 |
| Low Dose ARD-501 | DRUG | Phase PHASE2 | Autism Spectrum Disorder | COMPLETED | NCT06126653 |
| Placebo | DRUG | Phase PHASE3 | Hyperphagia | SUSPENDED | NCT06828861 |
| ARD-101 | DRUG | Phase PHASE3 | Hyperphagia | SUSPENDED | NCT07197034 |